# Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis

> **NCT00424398** · PHASE2,PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 107 (actual)

## Conditions studied

- Conjunctivitis, Allergic

## Interventions

- **DRUG:** Bepreve
- **DRUG:** Placebo
- **DRUG:** Bepotastine Besilate

## Key facts

- **NCT ID:** NCT00424398
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2013-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424398, "Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00424398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*